Samsung Biologics Co Ltd
- Branche
- Pharma R&D Outsourcing
- Börse
- Korea
- Land / Region
- Korea
- Mitarbeiter
- 5.195
- Website
- samsungbiologics.com
Zusammengesetzter Bewertungsbereich · konservativ 850,000–1,100,000 / fair 1,250,000–1,600,000 / optimistisch 1,900,000–2,300,000. Bei 1,430,000, Innerhalb des fairen Bereichs des inneren Werts.
Bei Veröffentlichung 1,336,000 (5. Juni 2026)
Noch keine Analysen zu dieser Aktie in Ihrer Sprache.
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Daten von EODHD, dargestellt in der Berichtswährung; nur zu Informationszwecken, keine Anlageberatung.
Geschichte
DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.
Branchenposition
DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.